This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Georges, R. N. Articles by Roth, J. A. Search for Related Content PubMed PubMed Citation Articles by Georges, R. N. Articles by Roth, J. A.

Prevention of Orthotopic Human Lung Cancer Growth by Intratracheal Instillation of a Retroviral Antisense K-ras Construct¹

Departments of Thoracic Surgery [R. N. G., T. M., Y. Z., N. Y., J. A. R.] and Tumor Biology [J. A. R.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

An orthotopic human lung cancer model in nu/nu mice was used to study the effect of an antisense K-ras (AS-K-ras) retroviral construct on tumor growth in vivo. A 2-kilobase genomic AS-K-ras DNA fragment linked to a ß-actin promoter was cloned into the LNSX retroviral vector. The recombinant construct was packaged into GP+envAm12 cells and titers greater than 10⁶ colony-forming units/ml were obtained. Irradiated (350 cGy) nu/nu mice were first inoculated intratracheally with 10⁵ H460a human large cell lung carcinoma cells which have a codon 61 mutation of the K-ras oncogene. Three days later they received intratracheal instillation of viral supernatant (5 x 10⁶ colony-forming units/ml) from either LNSX, LNSX-AS-K-ras, LNSX-sense-K-ras producer cells, or medium daily for 3 days. At autopsy, 30 days after tumor cell inoculation, 90% of the control mice had tumors whereas 87% of mice treated with the LNSX-AS-K-ras viral supernatant were free of tumors. The efficacy of the viral supernatant was dose dependent. Intratracheal administration of retroviral LNSX-AS-K-ras supernatant prevents the growth of human lung cancer cells implanted orthotopically in nu/nu mice.

¹ This study was partially supported by grants from the National Cancer Institute and NIH (ROI-CA45187) (J. A. R.), National Cancer Institute Training Grant CA-09611 (J. A. R.), gifts to the Division of Surgery from Tenneco and Exxon for the Core Laboratory Facility, the M. D. Anderson Cancer Center Support Grant CA16672, and a grant from the Mathers Foundation.

² To whom requests for reprints should be addressed, at The University of Texas M. D. Anderson Cancer Center, Department of Thoracic Surgery, Box 109, 1515 Holcombe Blvd., Houston, TX 77030.

Received 2/ 1/93. Accepted 3/ 5/93.

This article has been cited by other articles:

				H. S. Floyd, C. L. Farnsworth, N. D. Kock, M. C. Mizesko, J. L. Little, S. T. Dance, J. Everitt, J. Tichelaar, J. A. Whitsett, and M. S. Miller Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model Carcinogenesis, December 1, 2005; 26(12): 2196 - 2206. [Abstract] [Full Text] [PDF]

				A. A. Adjei and M. Hidalgo Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy J. Clin. Oncol., August 10, 2005; 23(23): 5386 - 5403. [Abstract] [Full Text] [PDF]

				Y. Zou, H. Fu, S. Ghosh, D. Farquhar, and J. Klostergaard Antitumor Activity of Hydrophilic Paclitaxel Copolymer Prodrug Using Locoregional Delivery in Human Orthotopic Non-Small Cell Lung Cancer Xenograft Models Clin. Cancer Res., November 1, 2004; 10(21): 7382 - 7391. [Abstract] [Full Text] [PDF]

				T. H. March, P. G. Marron-Terada, and S. A. Belinsky Refinement of an Orthotopic Lung Cancer Model in the Nude Rat Vet. Pathol., September 1, 2001; 38(5): 483 - 490. [Abstract] [Full Text] [PDF]

				A. A. Adjei Blocking Oncogenic Ras Signaling for Cancer Therapy J Natl Cancer Inst, July 18, 2001; 93(14): 1062 - 1074. [Abstract] [Full Text] [PDF]

				T. A. Steele Recent Developments in the Virus Therapy of Cancer Experimental Biology and Medicine, February 1, 2000; 223(2): 118 - 127. [Abstract] [Full Text]

				K. A. Gelmon, E. A. Eisenhauer, A. L. Harris, M. J. Ratain, and P. Workman Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment: Challenges for Drug Development? J Natl Cancer Inst, August 4, 1999; 91(15): 1281 - 1287. [Full Text] [PDF]

				M Roland and R M Rudd Genetics and pulmonary medicine bullet  7: Somatic mutations in the development of lung cancer Thorax, November 1, 1998; 53(11): 979 - 983. [Full Text]